Success Rate of Allergy Shots: Per-Allergen Breakdown
Success rate is allergen-specific, not a single number. Any source quoting a uniform percentage misrepresents the literature. Per-allergen: Hymenoptera venom >95% protection (Golden 2005; 2.7% vs 39.8% sting reactions, Boyle Cochrane 2012); grass ~80% medication reduction (Walker 2001); cat ~62% symptom reduction (Varney 1997); Alternaria 63.5% combined symptom score year 3 (Kuna 2011); birch ~40% symptom / ~50% medication (Bødtger 2002). Real-world ceiling: 43.9% reach maintenance (Tkacz 2021, n=103,207).
7 peer-reviewed sources
Allergy shot success rates by allergen: venom >95%, grass ~80% medication reduction, cat ~62%, Alternaria 63.5% (year 3). The Cochrane aggregate for seasonal rhinitis is symptom SMD −0.73. Any single 'success rate' for all allergens is unsupported by the literature.
The essentials
The success-rate numbers documented per allergen assume the extract matches the dominant sensitization — Curex at-home IgE testing with allergist review identifies that dominant allergen, so a patient pursuing immunotherapy can reasonably expect the trial-level per-allergen success rate, not a diluted multi-allergen-vial average.
Success rate is one of the most misrepresented metrics in allergy immunotherapy communications. A single percentage — any single percentage — is scientifically unjustifiable across all allergens, because: (1) extract standardization status varies enormously; (2) the strength of the RCT base varies from Cochrane-level evidence to essentially zero controlled evidence; (3) the endpoint used to define success varies by trial (symptom score, medication score, combined score, sting reaction incidence, QoL); and (4) the population studied varies (monosensitized European single-allergen trials vs polysensitized US multi-allergen practice).
Hymenoptera venom (highest success rate documented). Boyle RJ et al. (Cochrane 2012, PMID 23076950) found subsequent systemic sting reactions in 2.7% of VIT-treated patients versus 39.8% of untreated controls — a RR of 0.10 (95% CI 0.03–0.28). Golden DBK et al. (JACI 2005;115:439–447) states VIT prevents systemic reactions in >95% of treated patients: single-vespid VIT 85–90% effective; honeybee VIT 75–85% effective. These are the highest documented success rates in all of allergy immunotherapy.
Grass pollen (strongest aeroallergen evidence). Walker SM et al. (JACI 2001;107:87–93, DOI 10.1067/mai.2001.112027): approximately 49% symptom-score reduction and approximately 80% medication-score reduction versus placebo (P=.007). Durham SR et al. (NEJM 1999;341:468–475): durable ≥3-year post-treatment remission after a 3–4 year grass SCIT course.
Cat (Fel d 1). Alvarez-Cuesta E et al. (JACI 1994;93:556–566): significant improvement in combined symptom-medication score. Varney VA et al. (Clin Exp Allergy 1997;27:860–867): approximately 62% symptom reduction on natural cat-room challenge.
Ragweed. Creticos PS et al. (NEJM 1996;334:501–506, DOI 10.1056/NEJM199602223340804): significant in-season symptom-score reduction and reduced rescue-medication use.
Alternaria mold (pediatric). Kuna P et al. (JACI 2011;127:502–508, DOI 10.1016/j.jaci.2010.11.036): combined symptom-score reduction of 38.7% in year 2 and 63.5% in year 3 versus placebo. Tabar AI et al. (JACI 2019, DOI 10.1016/j.jaci.2019.02.029): Alt a 1 RCT confirmation.
Birch (European RCTs). Bødtger U et al. (Allergy 2002;57:297–305, DOI 10.1034/j.1398-9995.2002.1o3532.x): approximately 40% symptom-score and approximately 50% medication-score reduction.
Aggregate seasonal allergic rhinitis. Calderón MA et al. (Cochrane 2007, CD001936, DOI 10.1002/14651858.CD001936.pub2): symptom SMD −0.73 (95% CI −0.97 to −0.50) and medication SMD −0.57 (95% CI −0.82 to −0.33) across 51 RCTs and 2,871 patients.
Allergens with thin or absent success-rate data: mountain cedar (only ILIT proof-of-concept, Thompson CP et al., Ann Allergy Asthma Immunol 2020;125:311–318); non-Alternaria molds (Cladosporium, Aspergillus — essentially no controlled SCIT data); most insect-pollinated trees outside olive. Any percentage quoted for these allergens is extrapolated, not measured.
Real-world success ceiling: Only 43.9% of US AIT starters reach maintenance and 23.9% never returned after their first injection (Tkacz JP et al., Curr Med Res Opin 2021;37:957–965, DOI 10.1080/03007995.2021.1903848, MarketScan n=103,207). The per-allergen RCT success rates above apply to patients who complete the protocol — they do not adjust for the 56.1% US dropout rate.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
Per-allergen success rates documented in primary RCT evidence. These figures are trial-level estimates from controlled studies — real-world rates may be lower due to adherence, multi-allergen vial dilution, and sensitization-mismatch factors.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
The per-allergen success rate must also be compared against the success rate of alternative treatments — including FDA-approved SLIT tablets for the allergens that have them, and the at-home allergy shot, which delivers the same SCIT success profile without weekly clinic visits.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (allergy shots) | |||||
SLIT drops (off-label) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
For patients whose schedule cannot sustain the traditional weekly-injection commitment that caps real-world success at the 43.9% maintenance rate documented in Tkacz 2021, Curex delivers the allergy shot itself at home: a personalized SCIT serum sterile-compounded to USP <797> standards, prescribed by a board-certified allergist and self-administered as one weekly shot at home for $129/month. Your first dose and every dose change are supervised live over Zoom and a prescribed epinephrine auto-injector is confirmed on hand — the same per-allergen success profile without the in-clinic visit-frequency adherence cliff.
See if at-home shots are right for youFrequently asked questions
What is the success rate of allergy shots overall?
There is no single valid success rate for allergy shots across all allergens. The closest aggregate estimate is from the Cochrane meta-analysis by Calderón MA et al. (2007, CD001936): a symptom SMD of −0.73 across 51 RCTs and 2,871 patients in seasonal allergic rhinitis — a moderate-to-large effect size. But this aggregate conceals wide variation: venom immunotherapy achieves >95% protection against systemic sting reactions (Golden 2005), while conventional SCIT for mountain cedar or non-Alternaria molds has essentially no controlled trial evidence. The specific allergen is the most important variable in estimating success. Anyone quoting a uniform '85% success rate' or similar across all allergens is not accurately representing the published literature.
What is the success rate for allergy shots for bee stings?
Venom immunotherapy for bee (Hymenoptera) sting allergy is the most successful form of immunotherapy. Boyle RJ et al. (Cochrane 2012, PMID 23076950) found subsequent systemic sting reactions in only 2.7% of VIT-treated patients versus 39.8% of untreated controls — a risk ratio of 0.10 (95% CI 0.03–0.28). Golden DBK et al. (JACI 2005;115:439–447) states VIT prevents systemic reactions in more than 95% of treated patients overall; single-vespid VIT is 85–90% effective; honeybee VIT is 75–85% effective. Hunt KJ et al. (NEJM 1978;299:157–161) established the landmark controlled VIT trial. Protection commonly persists after completing a 3–5 year course, though relapse risk is higher with elevated baseline serum tryptase and honeybee venom specifically.
What is the success rate for allergy shots for dust mites?
For dust mite allergy, the strongest modern evidence base comes from SLIT-tablet (not SCIT) trials. Mosbech H et al. (JACI 2014;134:568–575, DOI 10.1016/j.jaci.2014.03.019, n=604) found significant inhaled corticosteroid reduction with maintained asthma control using dust mite SLIT-tablet. It is important not to silently extrapolate SLIT-tablet efficacy to compounded SCIT — these are different delivery routes and different regulatory product classes. SCIT for dust mite does have clinical trial support (ICS-sparing trends in SCIT HDM studies), but the most robust modern numerically precise RCT data for dust mite is SLIT-tablet. A board-certified allergist can discuss whether SCIT or SLIT is the better-evidenced option for your specific dust mite sensitization.
Does the success rate of allergy shots decrease with multiple allergens?
Potentially — polysensitized patients may have somewhat lower predictable response rates than monosensitized patients, based on analyses within the Calderón 2007 Cochrane dataset. Multi-allergen vials (common US practice) can dilute each component below its effective maintenance dose, potentially reducing per-component biological potency. Additionally, component-resolved diagnostics can distinguish genuine sensitization to a major allergen (e.g., Bet v 1 for birch, Fel d 1 for cat) from cross-reactive sensitization — patients genuinely sensitized to primary allergens respond more predictably. The success rate documented in European RCTs typically used single-allergen extracts, so the numbers may not transfer directly to US multi-allergen practice. A board-certified allergist experienced in SCIT can optimize vial composition to maximize expected success.
Does the success rate of allergy shots improve the longer you do them?
Yes — success rates improve with treatment duration up to approximately 3–4 years. Build-up produces partial and unreliable relief (Cox 2011 PP3). Most patients notice improvement between months 6–12. Maximum benefit accrues in years 2–3. Durham SR et al. (NEJM 1999) showed that 3–4 years is the minimum for durable post-treatment remission. Courses shorter than approximately 2 years are associated with weaker durability and higher relapse. The pediatric asthma-prevention benefit in the PAT study (Jacobsen 2007) also required a full 3-year course. There is no documented benefit to extending beyond 5 years for most patients — the standard recommendation is 3–5 years per Cox 2011 PP3, with discontinuation based on allergen type and individual response.
What success rate can I realistically expect from allergy shots?
Your realistic success rate depends on three factors: your specific allergen, whether you complete the full 3–5 year course, and whether the extract is correctly matched to your dominant sensitization. In ideal trial conditions, grass SCIT produces ~80% medication reduction (Walker 2001), cat SCIT ~62% symptom reduction (Varney 1997), and venom immunotherapy >95% sting protection (Golden 2005). But in real-world US practice, only 43.9% of starters reach maintenance (Tkacz 2021, MarketScan n=103,207) — meaning the majority of patients do not achieve these trial-level success rates because they drop out before the effective dose is established. Honest pre-treatment counseling should include not just the RCT success rates but also the 56.1% US dropout rate that limits real-world access to those rates.
Related Articles
Purpose of Allergy Shots: Mechanism & Clinical Intent
Allergy shots induce immune tolerance — IgE to IgG4. Three intents: symptom relief (Cochrane SMD −0.73), less medication, and durable disease modification.
Read moreIs There an Allergy Shot? Overview Guide | Curex
Yes — allergy shots (SCIT) have been in US use since 1911. Cochrane SMD −0.73 (51 RCTs). Works for environmental allergens and venom. NOT for food allergy. 3–5 yr course.
Read moreShould I Get Allergy Shots? Candidacy Guide | Curex
Should you get allergy shots? Cox 2011 PP3 defines 3 candidacy criteria. Strongest cases: venom (95%+ protection), pediatric asthma prevention OR 4.6. Honest contraindications.
Read moreAllergy Shots for Seasonal Allergies | Curex Guide
Yes, allergy shots work for seasonal allergies — Cochrane 51 RCTs found symptom SMD −0.73. Learn who qualifies, what the commitment is, and what 23.9% dropout means.
Read morePollen Allergy Shots: Efficacy & Evidence | Curex Guide
Pollen SCIT has the strongest immunotherapy RCT base: grass 49% symptom reduction (Walker 2001), ragweed NEJM 1996, birch 40% (Bødtger 2002). Full regional map inside.
Read moreDo Allergy Shots Work? Evidence & Honest Verdict | Curex
Do allergy shots work? Meta-analyses of 51 RCTs show 33-85% symptom reduction — but 20-50% of patients are low responders. Here's the honest evidence.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.